

**WHEREAS**, the Locational Running Annual Average for TTHM detected at the System during the second quarter of 2023 at sampling point 502 was 0.248 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for HAA5 detected at the System during the third quarter of 2023 at sampling point 501 was 0.241 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for HAA5 detected at the System during the third quarter of 2023 at sampling point 502 was 0.197 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for TTHM detected at the System during the third quarter of 2023 at sampling point 501 was 0.263 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for TTHM detected at the System during the third quarter of 2023 at sampling point 502 was 0.235 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for HAA5 detected at the System during the fourth quarter of 2023 at sampling point 501 was 0.219 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for HAA5 detected at the System during the fourth quarter of 2023 at sampling point 502 was 0.206 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for TTHM detected at the System during the fourth quarter of 2023 at sampling point 501 was 0.253 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for TTHM detected at the System during the fourth quarter of 2023 at sampling point 502 was 0.229 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for HAA5 detected at the System during the first quarter of 2024 at sampling point 501 was 0.210 mg/L, in violation of Rule 391-3-5-.18(7)(a); and

**WHEREAS**, the Locational Running Annual Average for HAA5 detected at the System during the first quarter of 2024 at sampling point 502 was 0.210 mg/L, in violation of Rule 391-3-5-.18(7)(a); and